Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies.

Garcia Bujalance L, Kelly M, Blackney M, Zeidman R, Skroumpelos A, Bijedic A, Sánchez-de la Rosa R, Plich A.

Value Health. 2015 Nov;18(7):A751. doi: 10.1016/j.jval.2015.09.2908. Epub 2015 Oct 20. No abstract available.

2.

An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder.

Ruff L, Zeidman R, Aracil J, Loveman C.

Value Health. 2014 Nov;17(7):A467-8. doi: 10.1016/j.jval.2014.08.1316. Epub 2014 Oct 26. No abstract available.

3.

The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies.

Blackney M, Kelly M, Zeidman R, Andreykiv M, Plich A.

Value Health. 2014 Nov;17(7):A393. doi: 10.1016/j.jval.2014.08.873. Epub 2014 Oct 26. No abstract available.

4.

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study.

Stephenson JJ, Kern DM, Agarwal SS, Zeidman R, Rajagopalan K, Kamat SA, Foley J.

Health Qual Life Outcomes. 2012 Dec 27;10:155. doi: 10.1186/1477-7525-10-155.

5.

DHHC2 is a protein S-acyltransferase for Lck.

Zeidman R, Buckland G, Cebecauer M, Eissmann P, Davis DM, Magee AI.

Mol Membr Biol. 2011 Oct-Nov;28(7-8):473-86. doi: 10.3109/09687688.2011.630682.

PMID:
22034844
6.

Analysis of protein acylation.

Zeidman R, Jackson CS, Magee AI.

Curr Protoc Protein Sci. 2009 Feb;Chapter 14:Unit 14.2. doi: 10.1002/0471140864.ps1402s55.

7.

Protein acyl thioesterases (Review).

Zeidman R, Jackson CS, Magee AI.

Mol Membr Biol. 2009 Jan;26(1):32-41. doi: 10.1080/09687680802629329. Epub 2008 Dec 29. Review.

8.

Signal transduction molecules in gliomas of all grades.

Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2009 Jan;91(1):19-26. doi: 10.1007/s11060-008-9683-5. Epub 2008 Sep 1.

9.

Identification of conserved amino acids N-terminal of the PKC epsilon C1b domain crucial for protein kinase C epsilon-mediated induction of neurite outgrowth.

Ling M, Trollér U, Zeidman R, Stensman H, Schultz A, Larsson C.

J Biol Chem. 2005 May 6;280(18):17910-9. Epub 2005 Feb 17.

10.

Induction of neurites by the regulatory domains of PKCdelta and epsilon is counteracted by PKC catalytic activity and by the RhoA pathway.

Ling M, Trollér U, Zeidman R, Lundberg C, Larsson C.

Exp Cell Res. 2004 Jan 1;292(1):135-50.

PMID:
14720513
11.

Protein kinase Cepsilon actin-binding site is important for neurite outgrowth during neuronal differentiation.

Zeidman R, Trollér U, Raghunath A, Påhlman S, Larsson C.

Mol Biol Cell. 2002 Jan;13(1):12-24.

12.
13.

Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation.

Svensson K, Zeidman R, Trollér U, Schultz A, Larsson C.

Cell Growth Differ. 2000 Dec;11(12):641-8.

14.
15.

Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells.

Zeidman R, Pettersson L, Sailaja PR, Truedsson E, Fagerström S, Påhlman S, Larsson C.

Int J Cancer. 1999 May 5;81(3):494-501.

Supplemental Content

Loading ...
Support Center